Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Fluid mixing from viscous fingering.

Jha B, Cueto-Felgueroso L, Juanes R.

Phys Rev Lett. 2011 May 13;106(19):194502. Epub 2011 May 12.

PMID:
21668165
2.

Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients.

Hida K, Lai SK, Suk JS, Won SY, Boyle MP, Hanes J.

PLoS One. 2011;6(5):e19919. doi: 10.1371/journal.pone.0019919. Epub 2011 May 27.

3.

Mucin dynamics and enteric pathogens.

McGuckin MA, Lindén SK, Sutton P, Florin TH.

Nat Rev Microbiol. 2011 Apr;9(4):265-78. doi: 10.1038/nrmicro2538. Review.

PMID:
21407243
4.

Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.

Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, Hanes J.

Nanomedicine (Lond). 2011 Feb;6(2):365-75. doi: 10.2217/nnm.10.123.

5.

Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus.

Yang M, Lai SK, Wang YY, Zhong W, Happe C, Zhang M, Fu J, Hanes J.

Angew Chem Int Ed Engl. 2011 Mar 7;50(11):2597-600. doi: 10.1002/anie.201006849. Epub 2011 Feb 18. No abstract available.

6.

Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models.

O'Neill MJ, Bourre L, Melgar S, O'Driscoll CM.

Drug Discov Today. 2011 Mar;16(5-6):203-18. doi: 10.1016/j.drudis.2011.01.003. Epub 2011 Jan 22. Review.

PMID:
21262379
7.

Lipid based therapy for ulcerative colitis-modulation of intestinal mucus membrane phospholipids as a tool to influence inflammation.

Schneider H, Braun A, Füllekrug J, Stremmel W, Ehehalt R.

Int J Mol Sci. 2010 Oct 25;11(10):4149-64. doi: 10.3390/ijms11104149. Review.

8.

Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines.

Wilson DS, Dalmasso G, Wang L, Sitaraman SV, Merlin D, Murthy N.

Nat Mater. 2010 Nov;9(11):923-8. doi: 10.1038/nmat2859. Epub 2010 Oct 10.

9.

Barrier properties of gastrointestinal mucus to nanoparticle transport.

Crater JS, Carrier RL.

Macromol Biosci. 2010 Dec 8;10(12):1473-83. doi: 10.1002/mabi.201000137. Epub 2010 Sep 20.

PMID:
20857389
10.

pH-Responsive nanoparticles for drug delivery.

Gao W, Chan JM, Farokhzad OC.

Mol Pharm. 2010 Dec 6;7(6):1913-20. doi: 10.1021/mp100253e. Epub 2010 Oct 27. Review.

11.

Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: Oral delivery using pH-responsive nanoparticles vs. subcutaneous injection.

Sonaje K, Lin KJ, Wey SP, Lin CK, Yeh TH, Nguyen HN, Hsu CW, Yen TC, Juang JH, Sung HW.

Biomaterials. 2010 Sep;31(26):6849-58. doi: 10.1016/j.biomaterials.2010.05.042. Epub 2010 Jun 17.

PMID:
20619787
12.

Nanoparticulate delivery of novel drug combination regimens for the chemoprevention of colon cancer.

Kanthamneni N, Chaudhary A, Wang J, Prabhu S.

Int J Oncol. 2010 Jul;37(1):177-85.

13.

Traffic of poly(lactic acid) nanoparticulate vaccine vehicle from intestinal mucus to sub-epithelial immune competent cells.

Primard C, Rochereau N, Luciani E, Genin C, Delair T, Paul S, Verrier B.

Biomaterials. 2010 Aug;31(23):6060-8. doi: 10.1016/j.biomaterials.2010.04.021. Epub 2010 May 14.

PMID:
20471085
14.

Characterization of particle translocation through mucin hydrogels.

Lieleg O, Vladescu I, Ribbeck K.

Biophys J. 2010 May 19;98(9):1782-9. doi: 10.1016/j.bpj.2010.01.012.

15.

Phospholipids and lipid-based formulations in oral drug delivery.

Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Quinkert RO, Martin F, Müller-Goymann C.

Pharm Res. 2010 Aug;27(8):1469-86. doi: 10.1007/s11095-010-0130-x. Epub 2010 Apr 22. Review.

PMID:
20411409
16.

Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs.

He CX, He ZG, Gao JQ.

Expert Opin Drug Deliv. 2010 Apr;7(4):445-60. doi: 10.1517/17425241003596337. Review.

PMID:
20201713
17.

Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.

Roger E, Lagarce F, Garcion E, Benoit JP.

Nanomedicine (Lond). 2010 Feb;5(2):287-306. doi: 10.2217/nnm.09.110. Review.

PMID:
20148639
18.

Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study.

Stremmel W, Braun A, Hanemann A, Ehehalt R, Autschbach F, Karner M.

J Clin Gastroenterol. 2010 May-Jun;44(5):e101-7. doi: 10.1097/MCG.0b013e3181c29860.

PMID:
20048683
19.

Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses.

Lai SK, Wang YY, Hida K, Cone R, Hanes J.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):598-603. doi: 10.1073/pnas.0911748107. Epub 2009 Dec 16. Erratum in: Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14371.

20.

Mucins in cancer: function, prognosis and therapy.

Kufe DW.

Nat Rev Cancer. 2009 Dec;9(12):874-85. doi: 10.1038/nrc2761. Review.

Supplemental Content

Support Center